Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
366
resultados
Última actualización
30/10/2026 [08:23:00]
Resultados 150 a 175 de 366
Resumen de: KR20260143067A
본 발명은 퇴행성 뇌질환 치료제 스크리닝용 TDP-43 변이체에 관한 것으로, TDP-43의 특정 영역 돌연변이를 통해 병리적 응집체인 아밀로이드 섬유 형성을 안정적으로 유도함으로써 실제 퇴행성 뇌질환의 병리 현상을 정확히 모사하는 질환 모델을 제공할 수 있다. 또한, 1,6-hexanediol에 대한 저항성을 갖는 고체상의 응집체를 형성하여, 액상 응집체의 병리적 고체상 전이를 제어할 수 있는 치료제 후보 물질을 신속하고 효율적으로 선별할 수 있다. 또한, 효모 및 포유동물 세포 시스템을 이용한 다각적 스크리닝을 통해 약물의 효능 및 세포 독성을 동시에 평가할 수 있는 신뢰성 높은 약물 탐색 플랫폼으로 활용할 수 있다.
Resumen de: KR20260143120A
0001a 본원은 LAMP1(Lysosome-Associated Membrane Protein 1) 및 OPTN(Optineurin)을 유효성분으로 포함하는, 신경 퇴행성 질환 진단용 바이오마커 조성물에 관한 것이다.
Resumen de: EP4814494A1
Provided is a method for identifying molecules and compounds involved in the modulation of lipid synthesis and uptake, wherein said molecule or compound blocks or activates SREBP maturation, comprising contacting cells with a molecule or compound to be tested and observing the presence or absence of domains in the endoplasmic reticulum membrane formed by cholesterol esters with cholesterol or, alternately, localizing SREBP proteins within the cell after said contacting, wherein the molecule or compound is identified as an inhibitor of SREBP maturation when ER domains form within the cell or, alternately, SREBP signal is localized more in the endoplasmic reticulum, whereas the molecule or compound is identified as an activator of SREBP maturation when ER domains are absent or, alternately, SREBP signal is localized more in the nucleus or when its target genes are elevated.
Resumen de: CN120795145A
The invention belongs to the technical field of biological medicine, and particularly relates to an anti-CXCL1 nano antibody and application thereof. The nano antibody comprises a heavy chain variable region targeting CXCL1, and the heavy chain variable region is composed of FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4; the amino acid sequence of the nano antibody and any one of SEQ ID NO.1-49 have at least 70% of sequence identity. The nano antibody has the advantages of small molecular weight, small immunogenicity and better solubility and stability, is beneficial to basic research and clinical tests, has potential diagnosis and treatment prospects for tumors, autoimmune diseases and neurological diseases, and has good practical application value.
Resumen de: WO2025059486A1
The present disclosure provides antibodies that specifically bind to human TDP-43 and methods of using these antibodies to treat patients with TDP-43-related diseases, including Amyotrophic Lateral Sclerosis (ALS).
Resumen de: CN122836330A
0001 本发明公开了一种阿尔茨海默症早筛传感器的制备方法、传感器及早筛方法，可分别制备电极基底与复合前驱液，将前驱液旋涂固化形成光电复合沟道层，经巯基乙酸与活化液表面活化后，孵育固定Aβ42适配体，再通过牛血清白蛋白封闭非特异位点，制得目标传感器。本发明融合光电化学与晶体管传感技术，实现沟道层光敏与生物识别功能一体化，依托光电协同效应放大微弱电势信号，检出限低、检测速度快、能耗低。本发明有效杜绝非特异性干扰，检测特异性与灵敏度优异，制备工艺简单、成本低廉且易于量产，创新了Aβ42检测思路，适配阿尔茨海默症早期低浓度样本筛查，具备极高的临床推广价值。
Resumen de: WO2026200905A1
The present application relates to an antibody specifically targeting α-synuclein and a use of the antibody. The present application also relates to a humanized antibody involved in the antibody and a use of the humanized antibody.
Resumen de: CN122836171A
本发明提供了用于测定外泌体蛋白的试剂在制备用于确定受试者衰老进程、用于在受试者中鉴定无症状期阿尔茨海默病和/或用于在受试者中区分无症状期阿尔茨海默病与正常衰老的试剂盒中的用途，其中，所述外泌体蛋白包括：C1QC、CO9、GP1BB、RSU1、A0A0G2JRQ6和ADA10。本发明基于六种特定外泌体蛋白的表达水平的动态变化速率分析，可精准区分无症状阿尔茨海默病与正常衰老，适用于AD早期筛查、MCI患者分层管理、疾病进展监测及健康体检，具有重要的临床实用价值和应用前景。
Resumen de: CN122833160A
本发明涉及生物医药技术领域，尤其是涉及基于CD9的PASC相关心血管系统症状风险评估应用。本发明提供了一种以CD9为核心分子标志物的风险评估体系，该体系能够在常规检测手段难以提供充分解释的情况下，为PASC相关心血管系统症状风险评估提供客观、可量化的分子层面参考依据。
Resumen de: CN122836331A
本发明涉及生物医药领域，公开了ATP6V0A1 K303琥珀酰化位点的应用，包括ATP6V0A1 K303琥珀酰化位点在制备用于筛选治疗神经退行性疾病的候选药物的试剂盒中的应用、筛选治疗神经退行性疾病的候选药物的体外方法以及用于筛选治疗神经退行性疾病的候选药物的试剂盒，ATP6V0A1蛋白的氨基酸序列如SEQ ID NO:1所示，K303位点为第303位赖氨酸，检测剂包括用于LC‑MS/MS检测修饰肽段NWFVKSuccinylVR的试剂。本发明通过将该位点琥珀酰化修饰水平用于候选药物筛选，使筛选结果与该位点琥珀酰化修饰水平相对应，为筛选使该位点修饰水平升高的候选药物提供技术基础。
Resumen de: CN122832039A
0001 本发明公开了一种靶向补体C5的多肽及其应用和产品，属于多肽制备技术领域。本发明首次提供了一种C5靶向多肽（命名为C548），该多肽可显著抑制炎症状态下膜攻击复合物（MAC）的组装，有效减轻炎症介导的组织损伤，为自身免疫性疾病及其他补体异常相关疾病提供了一种潜在的替代抗体治疗策略。
Resumen de: US20260298944A1
0000 Provided is a method for measuring a polypeptide aggregate in a sample, wherein the method comprises obtaining information regarding a concentration of the polypeptide aggregate in the sample using a calibrator, and the calibrator comprises a complex comprising: an oligopeptide comprising an epitope of the polypeptide aggregate; a hydrophilic polymer chain not comprising the epitope; and a carrier particle.
Resumen de: CN122831030A
本申请公开一种微流控卡盒和蛋白标志物检测方法，该微流控卡盒包括依次串联连接的多个试剂储存腔、与最下游试剂储存腔连通的反应腔、设置于相邻腔室之间流道上的控制阀、与反应腔连通的流体转移单元以及与各试剂储存腔连通的通气孔。本申请的微流控卡盒通过外部磁铁引导磁珠依次穿过各腔室完成靶标捕获、清洗、链霉亲和素偶联和核酸连接，仅在最下游腔室与反应腔之间通过流体转移单元实现液体转移以复溶冻干试剂并进行核酸扩增和信号检测。结构简单，无需精密泵阀，降低了制造成本和操作复杂度。封闭式设计杜绝交叉污染，且通用性强，仅需更换检测抗体即可适配不同靶标蛋白。
Resumen de: CN122827656A
本发明涉及磁共振成像技术利用，公开了一种基于H2O2含量检测的神经退行性疾病进展评估方法及系统，方法包括以下步骤：对最常见的神经退行性疾病阿尔兹海默病转基因APP/PS1小鼠模型进行H2O2含量的在体动态监测，得到动态监测结果；设置若干个监测时间点；在每个监测时间点利用，结合所述VDMP‑CEST序列和非均匀采样法对所述患者进行扫描；扫描时采用针对H2O2优化的饱和脉冲参数；基于扫描得到的数据，利用基于水信号参考的CEST定量方法，定量每个监测时间点H2O2的CEST信号强度。
Resumen de: CN122832097A
本发明公开了抗神经丝轻链蛋白的单克隆抗体及其应用，属于单克隆抗体技术领域，具体涉及抗神经丝轻链蛋白的单克隆抗体、抗体对及其在检测试剂盒中的应用；该单克隆抗体包括单克隆抗体2H12和单克隆抗体6E7。本发明提供的单克隆抗体具有高度特异性、高结合力和高亲和力，将其应用于制备神经丝轻链蛋白的免疫检测试剂，有助于显著提升免疫检测试剂的热稳定性，增强其抗钩状效应能力，提高对神经丝轻链蛋白的检测灵敏度和精密度，为神经系统疾病的临床诊断提供了可靠的工具。
Resumen de: WO2025182761A1
Provided is a method for detecting GFAP in a sample by immunoassay, the method including a first step for forming a complex of a first antibody and GFAP, and a second step for forming a complex of a second antibody and GFAP, the first antibody binding to a region consisting of amino acids at positions 111 to 115 in the amino acid sequence of GFAP.
Resumen de: WO2016191755A1
The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes methods of identifying a patient who would respond well to a T cell therapy or conditioning a patient prior to a T cell therapy so that the patient responds well to a T cell therapy. The conditioning involves administering one or more preconditioning agents prior to a T cell therapy and identifying biomarker cytokines prior to administering a T cell therapy.
Resumen de: JP2026531970A
0001 本開示は、ウイルスベクターを含有する試料中の少なくとも１つの宿主細胞タンパク質（ＨＣＰ）不純物を濃縮する、同定する、および／または特性評価するための方法を提供する。ＨＣＰ不純物は、ビーズベースのペプチドリガンドのライブラリーの利用を介して濃縮することができる。濃縮したＨＣＰは、続いて、酵素消化に供されてペプチドを生成し、このペプチドを液体クロマトグラフィー－質量分析（ＬＣ－ＭＳ）によって同定して、当該少なくとも１つのＨＣＰ不純物を特異的に同定するおよび／または特性評価することができる。 【選択図】図１Ａ
Resumen de: JP2026149362A
0001 【課題】被験者の糞便中の細菌の情報に基づき、低骨量又は低骨量リスクを検査する方法を提供する。 【解決手段】被験者の糞便中細菌におけるセガテラ・コプリの存在比率を取得する工程を含む、低骨量又は将来の低骨量リスクの検査方法。 【選択図】なし
Resumen de: CN122814900A
本发明公开了一种可以分辨APOE4基因杂合子和纯合子的指尖血试纸条。不仅可以用于快速检测受试人是否APOE ε4基因的携带者，而且还能进一步区分APOE ε4基因的携带者是杂合子还是纯合子。所述试纸条包括PVC底板，所述PVC底板上铺设有依次搭接的样本垫、滤血垫、结合垫、硝酸纤维层析垫和吸水垫；所述结合垫上涂有与抗人ApoE单克隆抗体结合的胶体金颗粒、彩色乳胶颗粒或荧光颗粒；所述硝酸纤维层析垫上靠近结合垫的一侧设有检测线T1和T2线、靠近吸水垫的一侧设有对照控制线C线，所述检测线T1线上涂有抗人ApoE4单克隆抗体，所述检测线T2线上涂有抗人ApoE多克隆抗体，所述对照控制线C线上涂有相应的抗IgG多克隆抗体。
Resumen de: CN122810244A
本发明公开了一种单克隆抗体或其抗原结合片段及其制备方法与应用。涉及生物医学技术领域。所述单克隆抗体或其抗原结合片段能够特异性结合DAP12蛋白，并且包含如SEQ ID NO：3至8所示的特定重链及轻链互补决定区序列；本发明提供的单克隆抗体或其抗原结合片段具有特异性强、灵敏度高、交叉反应低的特点，所述抗体及片段可广泛应用于蛋白质免疫印迹（Western Blot）、免疫组织化学（IHC）、免疫荧光（IF）等多种免疫学检测技术中，也可以用于后续开发诊断或治疗与DAP12信号通路异常相关的疾病的靶向药物或诊断试剂。
Resumen de: CN122814921A
本发明涉及生物医学检测技术领域，提供一种光激化学发光检测尿液样本中磷酸化tau蛋白的试剂盒，包括：供体微球，标记有抗人tau蛋白抗体；受体微球，标记有抗磷酸化tau蛋白抗体；供体微球和所述受体微球用于光激化学发光免疫分析。本发明的试剂盒采用双抗体夹心光激化学发光免疫分析法，通过供体微球与受体微球的协同作用产生化学发光信号，实现尿液样本中磷酸化tau蛋白的定量检测，具有均相检测、操作简便的特点。
Resumen de: WO2025037271A1
Provided herein are methods and assays for detecting central nervous system (CNS)-derived tau peptides in blood-based samples from subjects, involving the use of a capture antibody that binds to a tau epitope, and a detection antibody that binds to an epitope comprising amino acids residues that span the junction of Exon 4 and Exon 5 of CNS-derived tau.
Resumen de: US20260287589A1
0000 Disclosures herein are directed to methods and compositions for predicting high- and low-risk liver disease in patients. Based on the results achieved from the methods and compositions disclosed herein, liver disease patients can be classified into a prognostic risk group, which enables early diagnosis and prevention of HCC and other lethal complications. Methods and compositions disclosed herein substantially improve the poor prognosis of subjects having or at risk for one or more liver diseases.
Nº publicación: AU2025226208A1 24/09/2026
Solicitante:
MACFARLANE BURNET INST FOR MEDICAL RESEARCH AND PUBLIC HEALTH LIMITED
MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LIMITED
Resumen de: AU2025226208A1
The present invention relates to an antigen combination comprising Treponema pallidum (Tp) antigens. The present invention also relates to vectors, polynucleotides, host cells and methods for producing such antigen combinations. The present invention also relates to method and uses of such antigen combinations. The present invention also relates to compositions, assays and kits and the methods and uses thereof.
BOPI
Sede Electrónica
